[The clinical significance of the lamotrigine pharmacokinetic variability].

Aim: To estimate pharmacokinetic variability of lamotrigine (LTG) and its clinical significance.

Material And Methods: One hundred patients, including 74 women, aged from 18 to 77 years (38.23±14.

[Neurourological signs of chronic cerebral vascular diseases].

Disorders of urination, along with motor and cognitive disorders, are characteristic of different forms of chronic cerebral vascular diseases (CCVD). Irritation symptoms are more frequent in subcortical arteriosclerotic encephalopathy (SAE) and multi infarct hypertonic encephalopathy (MIHE). Overactive urine bladder syndrome (OUBS) caused by neurogenic detrusive hyperactivity manifests itself in frequent urination, nocturia and imperative enuresis and thus decreases quality of life and results in disability of patents with CCVD.

[Experience with application of trospium chloride in patients with neurogenic detrusor overactivity].

Overactive bladder (OAB) is observed in such brain diseases as stroke, hypoxic ischemic encephalopathy, Parkinson's disease (PD), multiple sclerosis (MS). Trospium chloride (spasmex) was used in OAB patients with MS (n = 87), stroke (n = 83), encephalopathy (n = 47) and PD (n = 36) in doses from 15 to 45 mg/day in 2 to 36 month courses. The response with minimal side effects was achieved in 94% patients.

[Prevention of contractures in post-stroke arthropathies].

Arthropathies develop in 15-20% of post-stroke paresis patients. A complex of rehabilitative measures including physical therapy (transcutaneous stimulation analgesia, heating etc.), kinesitherapy and anabolic hormones can prevent contractures if applied at the early rehabilitative stage.

[Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].

MAO B selective inhibitor was given to parkinsonism patients for several months. Positive effect was found in half of the patients irrespective of their age, time of the disease onset and its severity. The drug proved most effective in bradykinesia.

[Experience with the use of parlodel in the treatment of Parkinson patients].

The dopamine agonist parlodel was given to 42 patients with parkinsonism for several months. The drug proved effective in more than one-third of the patients. Different side-effects were observed in almost half of the patients.